AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
Price Chart
Executive Summary
Ascentage Pharma announced that six abstracts from its clinical studies were selected for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations. The abstracts cover data on its three lead drug candidates: olverembatinib (BCR-ABL inhibitor), lisaftoclax (Bcl-2 inhibitor), and alrizomadlin (MDM2-p53 inhibitor). While the data show promising efficacy signals (e.g., 91.3% CCyR rate for olverembatinib in CP-CML, 30% ORR for alrizomadlin combination in pediatric sarcomas), all three candidates remain investigational in the US and the press release contains no financial data, regulatory approvals, or guidance changes. The event is a routine scientific update with no material financial impact.
Actionable Insight
The ASCO data are incremental and do not change the near-term regulatory or commercial outlook. Monitor the POLARIS-2 and GLORA phase 3 readouts for olverembatinib and lisaftoclax, which are the key catalysts. The stock has historically shown high volatility around events (T+20 avg -10.81% on prior reports), so traders should be cautious about trading on abstract releases alone.
Key Facts
- Six abstracts selected for 2026 ASCO Annual Meeting (May 29–June 2, 2026), including three rapid oral presentations and three poster presentations.
- Olverembatinib (HQP1351) phase Ib data in Ph+ BCP-ALL/CML-LBP: 4 of 5 MRD+ patients achieved CR, 2 achieved MRD negativity.
- Olverembatinib second-line CP-CML data: 91.3% CCyR rate and 60.9% MMR rate at cycle 24 among 42 evaluable patients.
- Alrizomadlin (APG-115) ± lisaftoclax (APG-2575) in pediatric sarcomas: 30% ORR and 80% DCR in combination group; one CR in monotherapy.
- Olverembatinib in SDH-deficient GIST: 23.1% PR rate, median PFS 25.7 months (n=26).
- POLARIS-2 (olverembatinib phase 3 in CML) and GLORA (lisaftoclax phase 3 in CLL/SLL) are ongoing global registrational trials.
- All three drug candidates remain investigational in the US; no FDA approvals or regulatory decisions announced.
- No financial data, revenue, EPS, guidance, or deal values were disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release contains only clinical data updates with no revenue, earnings, or guidance figures.
Risk Factors
- All three drug candidates are investigational in the US; FDA approval is not guaranteed and timelines are uncertain.
- Phase 3 trials (POLARIS-2, GLORA) may fail to meet endpoints, which would severely impact valuation.
- The company has a history of negative stock reactions to news events (avg T+20 -10.81% on prior reports), suggesting market skepticism.
- No financial data in this release; the company's cash runway and revenue trajectory remain unaddressed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299861 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
9d ago
|
6-K
| $19.08 $17.20 | ▼ −9.85% | ▼ −7.10% | $17.07 (−10.53%) |
|
May 28, 2026
12d ago
|
6-K
| $20.01 $17.20 | ▼ −14.04% | ▼ −11.52% | $17.07 (−14.69%) |
|
May 28, 2026
13d ago
|
6-K
| $19.88 $17.87 | ▼ −10.11% | ▼ −10.06% | $17.07 (−14.13%) |
|
May 22, 2026
19d ago
|
6-K
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.86% | $17.07 (−18.75%) |
|
May 22, 2026
19d ago
|
Press Release
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.84% | $17.07 (−18.75%) |
|
May 13, 2026
28d ago
|
6-K
| $21.38 $18.99 | ▼ −11.18% | ▼ −10.02% | $17.07 (−20.16%) |
|
May 12, 2026
29d ago
|
6-K
| $21.16 $18.56 | ▼ −12.29% | ▼ −12.37% | $17.07 (−19.33%) |
|
Apr 22, 2026
7w ago
|
6-K
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.07 (−32.07%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.07 (−32.07%) |
|
Apr 20, 2026
7w ago
|
6-K
| $26.36 $23.37 | ▼ −11.34% | ▼ −12.26% | $17.07 (−35.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access